Core Viewpoint - The long-term follow-up results of the CAR-T cell therapy product Zevor-cel for treating relapsed/refractory multiple myeloma have been presented at the 22nd International Myeloma Society (IMS) Annual Meeting [1] Group 1: Product Information - Zevor-cel (CT053) is a fully human anti-BCMA CAR-T cell product designed for the treatment of multiple myeloma (MM) [1] - The National Medical Products Administration approved Zevor-cel for marketing on February 23, 2024, for adult patients with relapsed or refractory multiple myeloma who have progressed after at least three lines of treatment [1] - The product has received the Regenerative Medicine Advanced Therapy (RMAT) designation and orphan drug status from the FDA in 2019 [1] Group 2: Clinical Trial Updates - The updated results of the Phase I clinical trial were presented on September 17, 2025, at the IMS Annual Meeting, focusing on long-term follow-up of patients treated with Zevor-cel [1] - The presentation was titled "Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma" [1]
科济药业-B于2025年第22届IMS年会上呈列的赛恺泽 的研究成果更新